Success Metrics

Clinical Success Rate
90.5%

Based on 38 completed trials

Completion Rate
90%(38/42)
Active Trials
2(3%)
Results Posted
34%(13 trials)
Terminated
4(6%)

Phase Distribution

Ph phase_3
8
13%
Ph phase_2
21
33%
Ph phase_4
6
10%
Ph early_phase_1
1
2%
Ph phase_1
6
10%
Ph not_applicable
17
27%

Phase Distribution

7

Early Stage

21

Mid Stage

14

Late Stage

Phase Distribution59 total trials
Early Phase 1First-in-human
1(1.7%)
Phase 1Safety & dosage
6(10.2%)
Phase 2Efficacy & side effects
21(35.6%)
Phase 3Large-scale testing
8(13.6%)
Phase 4Post-market surveillance
6(10.2%)
N/ANon-phased studies
17(28.8%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

86.4%

38 of 44 finished

Non-Completion Rate

13.6%

6 ended early

Currently Active

2

trials recruiting

Total Trials

63

all time

Status Distribution
Active(7)
Completed(38)
Terminated(6)
Other(12)

Detailed Status

Completed38
unknown12
Terminated4
Not yet recruiting4
Recruiting2
Withdrawn2

Development Timeline

Analytics

Development Status

Total Trials
63
Active
2
Success Rate
90.5%
Most Advanced
Phase 4

Trials by Phase

Early Phase 11 (1.7%)
Phase 16 (10.2%)
Phase 221 (35.6%)
Phase 38 (13.6%)
Phase 46 (10.2%)
N/A17 (28.8%)

Trials by Status

enrolling_by_invitation12%
completed3860%
recruiting23%
terminated46%
unknown1219%
withdrawn23%
not_yet_recruiting46%

Recent Activity

Clinical Trials (63)

Showing 20 of 63 trialsScroll for more
NCT07040540

Hemodynamic Effects of Intradermal Methylene Blue During Breast Surgery Under General Anesthesia

Completed
NCT05092165Phase 2

Methylene Blue for the Prevention of Hypotension During Hemodialysis

Completed
NCT07494773Phase 1

Topical Methylene Blue-Photodynamic Therapy (MB-PDT) for Burn Wound Infection

Not Yet Recruiting
NCT06900140Phase 3

Adjunctive Methylene Blue in Septic Shock

Completed
NCT06052956Phase 2

Efficacy of Methylene Blue Photodynamic Therapy for Treatment of Deep Tissue Abscesses

Not Yet Recruiting
NCT06532240Phase 3

Methylene Blue for the Treatment of Septic Shock

Completed
NCT07212842Phase 2

Methylene Blue-Enhanced Ultrafiltration Improves Outcomes After Cardiopulmonary Bypass

Completed
NCT07179003Phase 2

A Phase 2 Study of Methylene Blue Photodynamic Therapy for Treatment of Breast Abscesses

Not Yet Recruiting
NCT07169487Phase 1

Adjunctive Methylene Blue for Immunotherapy-related CRS and ICANS: Phase I Study

Recruiting
NCT04635605Phase 2

Methylene Blue Treatment of COVID-19

Completed
NCT06887036Phase 2

Methylene Blue Treatment of Chronic Hepatitis B Virus Infection

Recruiting
NCT01847612Phase 3

Use of Indocyanine Green Cholangiography and Methylene Blue to Detect Postoperative Biliary Fistula After Hepatectomy

Completed
NCT02478281Phase 1

Safety, Tolerability, and Pharmacokinetic Study of Methylene Blue Following a 1 mg/kg Intravenous Dose in Healthy Adults

Completed
NCT04529265Not Applicable

Methylene Blue and Postoperative Neurocognitive Disorders

Completed
NCT06660680Phase 3

The Effect of Methylene Blue Infiltrating Injection on Anal Pain After Milligan-Morgan Surgery: a Randomized Controlled Clinical Study

Enrolling By Invitation
NCT02380573Phase 2

Effects of Methylene Blue in Healthy Aging, Mild Cognitive Impairment and Alzheimer's Disease

Completed
NCT06553144Not Applicable

Comparative Analysis of Photodynamic Therapy on Periapical Healing

Completed
NCT04054999Phase 4

Methylene Blue vs Cyanokit for Intraoperative Vasoplegic Syndrome in Liver Transplant Patients

Completed
NCT06024213

A French Observational Study of Indocyanine Green for Patients With Breast Cancer Having a Sentinel Lymph Node Biopsy.

Completed
NCT06306001Phase 2

Intravenous Methylene Blue for Treating Refractory Neonatal Septic Shock

Not Yet Recruiting

Drug Details

Intervention Type
PROCEDURE
Total Trials
63